Shanghai MicuRx Pharmaceutical (SHA:688373), a US subsidiary of Shanghai MicuRx Pharmaceutical, has filed a lawsuit against Medpace in an Ohio federal court over alleged contract breaches related to a clinical trial agreement, according to a Wednesday filing with the Shanghai bourse.
The dispute stems from Medpace's failure to meet agreed targets and refusal to return trial data. While a partial settlement was reached, unresolved claims remain, the filing said.
The financial impact is uncertain, and the case has yet to go to trial.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.